目的 探讨瑞格列奈治疗肾移植后糖尿病(post-transplantation diabetes mellitus， PTDM)的疗效和安全性。方法 收集2012-01至2014-06在我院确诊为肾PTDM并接受瑞格列奈治疗6个月的患者，观察治疗前和治疗后 1、3、6个月空腹血糖、餐后2 h血糖、糖化血红蛋白、谷丙转氨酶、谷草转氨酶、碱性磷酸酶、总胆红素、直接胆红素、白蛋白、总蛋白、肌酐、尿素氮、尿酸水平和他克莫司浓度。结果 共纳入病例32例，22例单用瑞格列奈即能达到满意疗效，剩余10例单用瑞格列奈血糖控制欠佳，采用瑞格列奈加甘精胰岛素血糖控制满意。治疗后 1、3、6个月时的空腹血糖，餐后2 h血糖较治疗前均明显降低，差异有统计学意义(P＜0.05);治疗6个月时糖化血红蛋白(6.20%±0.3%)水平较治疗前(7.50%±0.63%)明显降低(P＜0.05);治疗前后肝肾功能各项指标和他克莫司浓度变化无统计学意义;治疗过程中发生6人次低血糖反应，最低血糖为3.7 mmol/L，无严重低血糖发生。结论 瑞格列奈可作为肾PTDM患者一种安全有效的降糖药物。
Abstract
Objective To study the efficacy and safety of repaglinide therapy in patients with post-transplantation diabetes mellitus(PTDM). Methods To all the patients diagnosed as having PTDM,recrnited in this hospital from January 1,2009 to June 30, 2010 repaglinide was administered for 6 months. Glucose level, hepatic and renal function indicators and FK-506 concentration were examined at baseline, 1 month, 3 months and 6 months of repaglinide therapy. Results 32 patients were included. Except 10 patrents who required insulin glargine therapy due to their poor blood glucose control, the remaining 22 cases received satisfactory glycemic control with repaglinide alone. The levels of FBG, PBG at 1 month, 3 months or 6 months of treatment were significantly lower than those at baseline respectively (P<0.05). The level of Hb1AC at 6 months (6.20%±0.3%) was significantly lower than that at baseline(7.50%±0.63%;P＜0.05). Indicators of hepatic and renal functions and serum FK-506 concentration showed no significant change before and after repaglinide therapy. In the course of treatment hypoglycemia occurred 6 times, in which the lowest blood glucose level was 3.7 mmol/L, no severe hypoglycemia oleveloped. Conclusions Repaglinide can be a safe and effective therapy in patients with PTDM.
关键词
移植后糖尿病 /
瑞格列奈 /
干精胰岛素 /
疗效 /
安全性
Key words
posttransplantation diabetes mellitus /
repaglinide /
efficacy /
safety
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Jelmesaeth J, Jessen T, Hartmann A. Diagnosing of PTDM[J]. Transplantation, 2003, 75(10):1761.
[2] Eckhard M, Schindler R A, Renner F C, et al. New-onset diabetes mellitus after renal transplantation[J]. Transplant Proc, 2009, 41(6): 2544-2545.
[3] Gomes M B, Cobas R A. Post-transplant diabetes mellitus[J]. Diabetol Metab Syndr, 2009, 1(1): 14.
[4] Gnatta D, Keitel E, Heineck I, et al. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study[J]. Transplant Proc, 2010, 42(2): 475-478.
[5] Pérez-Flores I, Sánchez-Fructuoso A, Calvo N, et al. Incidence and risk factors for the metabolic syndrome and posttransplant diabetes in renal transplant recipients taking tacrolimus[J]. Transplant Proc, 2010, 42(8): 2902-2904.
[6] Davidson J A, Wilkinson A. New-onset diabetes after transplantation 2003 international consensus guidelines[J]. Diabetes Care, 2004,27(3):805-812.
[7] Turk T, Pietruck F, Dolffa S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation[J]. Am J Transplant, 2006, 6(4): 842-846.
[8] 吴谊青,王少艳,毕 会.瑞格列奈及罗格列酮对肾移植后糖尿病患者的疗效[J]. 天津医药, 2010, 38(4): 276-278.
[9] Johansen O E, Birkeland K I. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review [J]. Am J Cardiovasc Drugs, 2007,7(5):319-335.
PDF(534 KB)
